Clinical Trial News and Research

RSS

Docetaxel given after doxorubicin reduces recurrence

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the National Cancer Institute.

9 Jan 2008

Trichloroethylene chemical - widely used in industry - is a risk factor for parkinsonism

Parkinson's disease, the most common neurodegenerative movement disorder caused by aging, can also be caused by pesticides and other neurotoxins.

8 Jan 2008

Oncolytics Biotech announces new reovirus, cyclophosphamide research

Oncolytics Biotech Inc. has reported that a research group led by Dr. Richard Vile of the Mayo Clinic College of Medicine in Rochester, Minnesota, published the results of its work testing the antitumor efficacy and safety of various combinations of reovirus and cyclophosphamide in vivo.

8 Jan 2008

Daiichi Sankyo, Lilly submit NDA for investigational antiplatelet drug, Prasugrelin U.S.

Daiichi Sankyo Company, Limited and Eli Lilly and Company have announced that on Wednesday, Dec. 26, 2007, they submitted a New Drug Application (NDA) for prasugrel to the U.S. Food and Drug Administration (FDA).

7 Jan 2008

Novel anti-tumor compound

Researchers at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important "intercept points" for cancer cells.

4 Jan 2008

FDA clears first rapid blood test for MRSA

The U.S. Food and Drug Administration (FDA) has announced it has cleared for marketing the first rapid blood test for the drug-resistant staph bacterium known as MRSA (methicillin-resistant Staphylococcus aureus), which can cause potentially deadly infections.

3 Jan 2008

FDA approves Hi-Flex mobile bearing knee prostheses

Mitchell Sheinkop, M.D., will be the first in the U.S. to surgically implant the just-approved Nex Gen LPS-Flex mobile bearing knee on February 20, 2008 at the Neurologic and Orthopedic Hospital of Chicago.

3 Jan 2008

Three-drug cocktail improves outcomes in glioblastoma multiforme

New research at Wake Forest University Baptist Medical Center suggests that a three-drug cocktail may one day improve outcomes in patients with glioblastoma multiforme (GBM), a type of brain tumor with a dismal prognosis.

2 Jan 2008

Fish oil benefits

It's good news that we are living longer, but bad news that the longer we live, the better our odds of developing late-onset Alzheimer's disease.

28 Dec 2007

Study shows that antiangiogenic agent delays progression of advanced breast cancer

The positive results of the first nationwide clinical study showing the benefits of an antiangiogenic agent in breast cancer therapy are reported in the Dec. 27 issue of the New England Journal of Medicine.

28 Dec 2007

Personalized medicine will alter treatment of genetic disorders

One of the nation's pre-eminent genetic researchers, Eric Hoffman, PhD, of Children's Research Institute at Children's National Medical Center, predicts that in relatively short order, medicine's next innovation--individualized molecular therapies--will have the unprecedented ability to treat muscular dystrophies, and other disorders.

28 Dec 2007

FDA approves Voluven for blood loss post surgery

The U.S. Food and Drug Administration has approved Voluven, an intravenous solution that prevents and treats a dangerous loss of blood volume, a condition that sometimes occurs during and after surgery.

28 Dec 2007

Cardiac stem cell therapy research

Since the year 2000, much has been learned about the potential for using transplanted cells in therapeutic efforts to treat varieties of cardiac disorders.

28 Dec 2007

Bevacizumab found to improve survival for patients with advanced breast cancer

Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an anti-angiogenic therapy.

28 Dec 2007

Anthrax vaccine will add to America's arsenal against bioterrorism

A company, based in Rockville, Maryland in the USA, with the help of government funding, has used the human genome to develop a vaccine that may give protection from anthrax.

19 Dec 2007

Researchers initiate gene therapy trial in patients with advanced skin cancer

Researchers at the Ireland Cancer Center of University Hospitals Case Medical Center are the first in the region to have joined a nationwide clinical trial to evaluate the effectiveness of a gene therapy in patients with advanced melanoma which is aimed to help a patient ' s own immune system fight their cancer.

18 Dec 2007

Factors associated with survival in advanced laryngeal cancer

Type of treatment, sex, race and insurance status are associated with survival rates among patients with advanced laryngeal cancer, according to a report in the December issue of Archives of Otolaryngology-Head & Neck Surgery.

18 Dec 2007

New study looks at airway bypass treatment for emphysema

Researchers at Sarasota Memorial Health Care System have announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a significant new, minimally-invasive option for those suffering with advanced widespread emphysema.

18 Dec 2007

New drug that cuts risk of cardiovascular disease shows promise

The first clinical trial of a new kind of drug to cut the risk of cardiovascular disease has been found safe and effective at dropping levels of "bad" low density lipoprotein (LDL) cholesterol by as much as 40 percent.

18 Dec 2007

Eli Lilly and BioMS Medical announce licensing and development agreement

Eli Lilly and Company and BioMS Medical Corp. have announced that the two companies have entered into a licensing and development agreement granting Lilly exclusive worldwide rights to BioMS Medical's lead multiple sclerosis (MS) compound, MBP8298.

18 Dec 2007